12 results about "Leuprorelin" patented technology

The sustained-release formulation of this invention, with its increased initial release, exhibits a rapid release effect within 24 hours after administration, followed by a sustained-release effect, thus simultaneously achieving both prolonged efficacy and rapid initial release. The sustained-release formulation of this invention, containing microspheres of leuprorelin, possesses excellent bioavailability and has been proven safe in humans; therefore, it can be effectively and safely used to treat various luteinizing hormone-releasing hormone-related diseases such as endometriosis, uterine fibroids, prostate cancer, premenopausal breast cancer, and central precocious puberty.

The invention provides a preparation method of leuprorelin acetate microspheres, and relates to the technical field of drug microspheres. The leuprorelin acetate microspheres are prepared by adopting a W / O / W multiple emulsion method, and the particle size and particle size distribution of the leuprorelin acetate microspheres and the release rate of the leuprorelin acetate are adjusted by reducing the concentration of the leuprorelin acetate in an inner water phase, improving the concentration of polylactic acid in an oil phase and the weight and time of water added in a water supplementing method. Therefore, the leuprorelin acetate microspheres which are high in drug loading content, low in dichloromethane residual rate and stable in drug release are obtained while the loss of leuprorelin acetate is reduced.

This invention belongs to the field of pharmaceutical synthesis, specifically relating to a method for synthesizing leuprorelin impurities. The method uses a specific intermediate, Fmoc-Orn(Pcm)-OH, as a reactant, which not only improves the yield and purity of the synthesized product but also simplifies the synthesis steps, reduces material costs, and is suitable for large-scale industrial production.

Liquid-liquid polymer leuprolide acetate (LA) formulations comprising a biodegradable polymer and biocompatible solvent, and methods of using the formulations.

The invention belongs to the field of drug sustained release preparations, and provides an ovulation inducing preparation for improving fertility and a preparation method thereof. The core-shell structure microsphere design is adopted, leuprorelin acetate is entrapped in the core of the polylactic acid microsphere, and covalently anchored amido bond connection is formed through an end group activated polylactic acid NHS ester intermediate and a chitosan-sodium tripolyphosphate ion network shell layer, so that the high stability of the shell layer is realized; by optimizing the compounding use of the internal phase stabilizer and the freeze-drying protective agent, the particle size distribution D50 of the microspheres is controlled to be 10-60 microns, the thickness of the shell layer is controlled to be 0.05-5 microns, and high encapsulation efficiency, good drug slow release performance and excellent storage stability are realized. The technical problems that in an existing peptide medicine core-shell microsphere system, a shell layer is prone to falling off, the medicine is suddenly released, and the stability is poor after freeze-drying are solved, and the peptide medicine core-shell microsphere has the advantages of being high in encapsulation efficiency, controllable in release and good in biocompatibility and has wide application value in the technical field of assisted reproduction.

The present technology relates to multi-dose injection pens, pharmaceutical compositions of leuprolide and combinations thereof. The multi-dose injection pens may be configured to contain multiple doses of leuprolide and to administer a single dose of leuprolide.

A liquid-liquid polymer leuprorelin acetate (LA) formulation comprising a biodegradable polymer and a biocompatible solvent, and methods of using the formulation.

The present application discloses Lactobacillus reuteri and its application in relieving perimenstrual syndrome, and relates to the technical field of biology. Limosilactobacillus reuteri ​ Lactobacillus reuteri (Lactobacillus reuteri) -NCU-37 was preserved in China General Microbiological Culture Collection Center on February 24, 2025, and the address is No. 1, Xibaixili, Chaoyang District, Beijing, and the preservation number is CGMCC NO. 33627. The Lactobacillus reuteri -NCU-37 of the present application can relieve perimenstrual syndrome induced by leuprolide in assisted reproductive treatment, specifically relieve perimenstrual syndrome and related emotional disorders (including anxiety, depression and insomnia), improve the hormone level of infertile women with perimenstrual syndrome, and relieve the symptoms of infertile women with perimenstrual syndrome by regulating intestinal flora diversity.

Compositions and methods for suppressing ovarian function in subjects with hormone receptor-positive breast cancer.

The present technology relates to multi-dose injection pens, pharmaceutical compositions of leuprolide and combinations thereof. The multi-dose injection pens may be configured to contain multiple doses of leuprolide and to administer a single dose of leuprolide.

The invention belongs to the technical field of preparation of leuprorelin, and particularly relates to an improved leuprorelin sustained release microsphere and a preparation method of the improved leuprorelin sustained release microsphere. Comprising the following components: 10-15 parts of leuprorelin, 60-80 parts of a polylactic acid-glycolic acid copolymer, 3-6 parts of an amino-containing hydrophilic modifier, 1-3 parts of a water-soluble stabilizer, 2-4 parts of a buffer agent and 0.6-1.2 parts of an emulsifier. Wherein the molar ratio of lactic acid to glycolic acid in the polylactic acid-glycolic acid copolymer is (1-3): 1, and the viscosity average molecular weight of the polylactic acid-glycolic acid copolymer is 30000-80000Da. The amino-containing hydrophilic modifier and the polylactic acid-glycolic acid copolymer form a synergistic effect, so that the hydrophobicity of the sustained-release microsphere is remarkably reduced, a core-shell structure is formed, and the release period of leuprorelin is further prolonged.